![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Rugo, H. S.; Dieras, V.; Gelmon, K. A.; Finn, R. S.; Slamon, D. J.; Martin, M.; Neven, P.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. Huang; Iyer, S.; Johnston, S.; Ettl, J. und Harbeck, N.
(2018):
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
In: Annals of Oncology, Bd. 29, Nr. 4: S. 888-894
Dieras, V.; Harbeck, N.; Joy, A. A.; Gelmon, K. A.; Ettl, J.; Verma, S.; Lu, D.; Gauthier, E. R.; Schnell, P.; Mori, A.; Rugo, H. S. und Finn, R. S.
(2017):
PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L).
In: Annals of Oncology, Bd. 28
Rugo, H.; Dieras, V.; Gelmon, K. A.; Finn, R.; Slamon, D.; Miguel, M.; Neven, P.; Ettl, J.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. H.; Iyer, S.; Johnston, S. und Harbeck, N.
(2016):
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naive postmenopausal patients with ER+HER2-metastatic breast cancer (MBC): results from PALOMA-2.
In: Annals of Oncology, Bd. 27